Li Shi

 

Li Shi, Ph.D.,

CEO, Shanghai Zerun Biotechnology Co., Ltd

Vice President, Walvax Biotechnology Co., Ltd

 

Dr. Li Shi is currently leading Zerun Bio focusing on human vaccine development and commercialization. Zerun Bio has been recognized by the national governement as a New and High-tech Enterpreure and achieved success M&A with Walvax in 2013. Prior to joining Zerun Bio in early 2011, Dr. Shi had 25 years of experience in USA for vaccine and protein product development and most of the time he was working with Merck. He made multiple key contributions to Merck’s Gardasil® vaccine development and involved from research stage to clinical developments and commercialization. The success of Gardasil® vaccine, allowed Merck team received 2006 ACS Best Bioprocess Award, and 2007 World Pre-Galen Award, called world pharmaceutical industry Nobel Prize. Dr. Shi also served as a senior director leading three teams in Genzyme for technology development and contributed to multiple gene therapgy, protein, and mab product development and manufacturing support activities.

 

Dr. Shi received BS/MS from Peking University, Ph.D. from University of California, and postdoctoral and MBA trainings from Scripps and Lehigh University, respectively. He has over 140 paper, patent, and presentation publications and served as reviewer/editor for 12 international journals and NIH fund. He is a winner of W. H. Person’s Award of American Chemical Society, a former president and co-founder of SAPA(GP). He currently serves as a council member in DIA-China advisory committee, USP global biologics expert committee, and Shanghai Biopharma Industrial Association. He is also a winner of both national and Shanghai “1000 talent” expert prizes.